Kineta Email Format
Biotechnology ResearchWashington, United States11-50 Employees
Kineta is a clinical-stage biotechnology company focused on developing novel immunotherapies for oncology to address cancer immune resistance. The company is based in Seattle, Washington, United States, and employs between 11 and 50 people. It operates in the biotechnology research industry and maintains a website at https://kinetabio.com. Kineta has developed a VISTA-targeting monoclonal antibody program, including candidates such as KVA12123 (also referred to as KVA1213 in some sources), which has been studied in early-phase clinical settings. In June 2025, TuHURA Biosciences completed the acquisition of Kineta, with Kineta’s antibody asset renamed TBS-2025 as part of TuHURA’s late-stage immuno-oncology pipeline.